Answers are grounded in this paper and cite their sources.
Introduction: A proportion of patients with multiple myeloma (MM) are older and/or have comorbidities, requiring dose adjustments. Data from OPTIMISMM (NCT01734928) supported the use of pomalidomide, bortezomib, and dexamethasone (PVd) for treating relapsed/refractory MM. This subanalysis of OPTIMISMM assessed outcome by frailty and/or bortezomib dose adjustment. Methods: Patient frailty (non-frail vs. frail) was classified using age, Charlson Comorbidity Index, and Eastern Cooperative Oncology Group performance status. Data from patients requiring a bortezomib dose reduction, interruption, and/or withdrawal during PVd treatment were assessed. Results: Among 559 patients, 93/281 (33.1%) and 93/278 (33.5%) patients who received PVd and bortezomib and dexamethasone (Vd), respectively, were frail. Overall response rate (ORR) and median progression-free survival (PFS) were higher in non-frail versus frail with PVd treatment (ORR, 82.8% vs. 79.6%; PFS, 14.7 vs. 9.7 months); significantly higher than with Vd regardless of frailty. Grade ≥3 treatment-emergent adverse events (TEAEs) were higher with PVd versus Vd, regardless of frailty. Discontinuations of PVd were lower in non-frail versus frail patients (19.2% vs. 30.1%); median duration of treatment was similar (DoT; 8.8 vs. 8.9 months, respectively). Patients who received PVd with a bortezomib dose adjustment (n = 240) had a longer median DoT (9.3 vs. 4.5 months) and PFS (12.1 vs. 8.4 months) versus those without. Conclusion: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT versus Vd, despite higher frequency of grade ≥3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty. Microabstract: This subanalysis of OPTIMISMM demonstrates that patients who received pomalidomide, bortezomib, and dexamethasone (PVd) had a higher ORR and longer median PFS versus bortezomib and dexamethasone, regardless of frailty. Bortezomib dose adjustment allowed longer PVd treatment, with improved efficacy and fewer discontinuations. Therefore, these data support the use of PVd for the treatment of relapsed/refractory multiple myeloma in frail patients.
No takes yet. Share an insight, caveat, or question.
Oriol et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: